HCHenry Chubb

Henry Chubb

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Henry Chubb has a total of 430 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predictors of Response to Cardiac Resynchronization Therapy in Pediatric Patients and Patients With Congenital Heart Disease

    by Henry Chubb, Douglas Mah, Maully Shah, Kimberly Y. Lin, David Peng, Benjamin W. Hale, Lindsay May, Susan Etheridge, William Goodyer, Scott R. Ceresnak, et al.

    BACKGROUND: Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric patients and patients with congenital heart disease with reduced systemic ventricular ejection fraction (SVEF). However, the identification of optimal responders is challenging. This study aimed to identify predictors of response to CRT in children and patients with congenital heart disease at 5 large quaternary referral centers. METHODS: Patients were aged P =0.013), biventricular circulation ( P =0.022), systemic left ventricle ( P =0.021), and conduction delay to the lateral wall of the systemic ventricle ( P =0.01) were associated with a positive response. For the assessment of the secondary outcome, 324 controls were identified. Median follow-up is 5.1 (interquartile range, 2.0–8.6) years. Almost all subgroups demonstrated improved SVEF trend with CRT, except those with systemic right ventricle ( P =0.69) or without prior single-site pacemaker ( P =0.20). CONCLUSIONS: CRT in children and patients with congenital heart disease frequently results in an improvement in SVEF. Those with lower SVEF, conduction delay to the lateral wall of the systemic ventricle, and those with a systemic left ventricle are most likely to respond.


  • Authors Insights on the Updated International Society for Heart and Lung Transplantation Guidelines for the Management of Pediatric Heart Failure (Update From 2014)

    by Shelley D. Miyamoto, Claire Irving, Estela Azeka, Rachele Adorisio, Elizabeth D. Blume, Carmel Bogle, Henry Chubb, Jennifer Conway, Melissa K. Cousino, Jonathan Edelson, et al.


  • Leadless and extravascular cardiac resynchronization therapy: the future for CRT?

    by Steven Niederer, Henry Chubb, Kenneth C. Bilchick, Christopher Aldo Rinaldi


  • Early Post‐Operative Versus Late Arrhythmias After Heart Transplant at a Pediatric Center: Incidence, Management, and Outcomes

    by Kristen L. Dammeyer, Kara S. Motonaga, Henry Chubb, Elizabeth L. Profita, Seth A. Hollander

    Background: Arrhythmias in pediatric heart transplant patients have historically raised concerns for acute rejection, often prompting invasive evaluation and empiric treatment. Despite this, the association of post‐transplant arrhythmias with adverse outcomes remains understudied. Methods: This is a retrospective single center review of pediatric patients who underwent heart transplant between 01/2014 and 12/2022. Arrhythmias were classified as early ( 14 days post‐transplant) and as atrial, ventricular, or bradyarrhythmias. Adverse outcomes including death, re‐transplantation, acute cellular rejection, acute antibody‐mediated rejection, and cardiac allograft vasculopathy were compared by chi‐squared or Fisher Exact test for those with and without arrhythmias. Results: Among 184 patients, 116 (63%) had at least 1 arrhythmia (284 total arrhythmia episodes). Overall, 99 (35%) arrhythmia episodes occurred in the early post‐operative period and 137 (48%) arrhythmia episodes were ventricular. Anti‐arrhythmic therapy was started for 69 (24%) arrhythmia events. There were 42 biopsies prompted by arrhythmia, yielding a new diagnosis of acute cellular rejection in 2 (5%) patients and antibody mediated rejection in 1 (2%) patient. No biopsies prompted by arrhythmia in the early post‐transplant period were positive for rejection. Compared to those without arrhythmia, patients with at least one arrhythmia episode were not at increased risk of cardiac allograft vasculopathy, any post‐transplant rejection, retransplantation, or death ( p = 0.26–0.78). Conclusions: Post‐transplant arrhythmias occur commonly in pediatric heart transplant patients but are not clearly associated with rejection or adverse outcomes. Further study in larger patient populations is necessary to better understand the significance of post‐transplant arrhythmias.


  • Cardiac resynchronization in congenital heart disease

    by Henry Chubb, Heather M. Giacone

  • Extended Rhythm Monitoring to Assess for Ventricular Arrhythmias After Transcatheter Pulmonary Valve Replacement With the Harmony Valve

    by Jeffrey K. Yang, Laura Wattenbarger, Anne C. Taylor, Henry Chubb, Anitra W. Romfh, Lynn F. Peng, Scott R. Ceresnak, Anne M. Dubin, Doff B. McElhinney

    BACKGROUND: Varying rates of nonsustained ventricular tachycardia (NSVT) have been reported early after transcatheter pulmonary valve replacement (TPVR) with the Harmony valve, but data regarding rhythm outcomes beyond hospital discharge are limited. This study aims to characterize ventricular arrhythmias after Harmony TPVR from implant through mid-term follow-up. METHODS: Ventricular arrhythmia data from postimplant telemetry and follow-up extended rhythm monitoring (ERM) were analyzed after Harmony TPVR. RESULTS: Fifty-four patients with tetralogy of Fallot (n=39), valvar pulmonary stenosis (n=10), or pulmonary atresia with intact ventricular septum (n=5) were studied; 22% had prior NSVT and 24% were on prior rhythm medication. On postimplant telemetry, 27 patients (50%) had NSVT, including 1 who had torsade de pointes, but most had <5 episodes. Pre-TPVR NSVT or rhythm medications, diagnosis other than tetralogy, and substantial device contact with the myocardium were associated with more frequent NSVT on telemetry. Ten patients (19%) were started on a new antiarrhythmic medication. On discharge ERM, 37% of patients had NSVT, most with <5 episodes and only 13% with NSVT beyond 5 days post-discharge. On follow-up ERM, 14% of patients had a single episode of NSVT and 1 had 5 episodes. During follow-up, antiarrhythmic medications were discontinued in 8 of 10 patients and no patients died or had sustained ventricular tachycardia. CONCLUSIONS: NSVT and ventricular ectopy were common early after TPVR but were infrequent in most cases and diminished rapidly after discharge. The incidence of NSVT on follow-up ERM was similar to preimplant incidence. Few patients had antiarrhythmic medications initiated, and most were discontinued on follow-up. There were no major arrhythmic events after discharge.


  • Open Access

    Predictors of Response to Cardiac Resynchronization Therapy in Pediatric and Congenital Heart Disease Patients

    by Henry Chubb, Douglas Y Mah, Maully J. Shah, Kimberly Yee Lin, David Ming-Shen Peng, Benjamin W Hale, Lindsay J May, Susan Etheridge, William Rowland Goodyer, Scott R Ceresnak, et al.

    Background: Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection fraction (EF). However, the identification of optimal responders is challenging. Objective: To identify predictors of response to CRT in children and CHD patients at 5 large quaternary referral centers. Methods: Patients were <21 years or had CHD; had SVEF <45%; symptomatic heart failure; and significant electrical dyssynchrony prior to CRT. Primary outcome was defined as an ordinal response at 6/12months: (1) Improved EF [≥5%], (2) Unchanged SVEF, (3) Worse SVEF. Secondary outcome utilized a propensity score-matched control cohort. Response to CRT was defined using longitudinal trajectory of SVEF up to latest follow-up. Results: In total, 167 eligible CRT recipients were identified across the 5 centers. 150 had comprehensive data at 6/12months: 96(64%) with improved SVEF, 26(17%) unchanged, 28(19%) worsened. Mean increase in SVEF was 11% [IQR 3-21%]. On univariable ordinal regression, lower SVEF (p=0.013), biventricular circulation (p=0.022), systemic LV (p=0.021), and conduction delay to lateral wall of SV (p=0.01) were associated with positive response. For assessment of secondary outcome, 324 controls were identified. Mean follow-up 4.2(±3.7) yrs. Almost all subgroups demonstrated improved SVEF trend with CRT, except those with systemic RV (p=0.69) or without prior single site pacemaker (p=0.20). Conclusion: CRT in children and CHD patients frequently results in an improvement in SVEF. Those with lower SVEF, conduction delay to lateral wall of the SV and those with systemic LV are most likely to respond. Condensed Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection fraction (EF). However, the identification of optimal responders is challenging. In this multicenter study, pediatric and CHD CRT recipients with heart failure and EF<45% were identified. The primary outcome was change in EF at 6/12months. Those with lower baseline SVEF, conduction delay to lateral wall of the SV and/or systemic LV were most likely to respond to CRT. When compared to propensity score-matched controls, the CRT groups also demonstrated a significantly better long-term EF trajectory.

  • Multisite Validation of a Functional Assay to Adjudicate SCN5A Brugada Syndrome–Associated Variants

    by Joanne G. Ma, Matthew J. O’neill, Ebony Richardson, Kate L. Thomson, Jodie Ingles, Ayesha Muhammad, Joseph F. Solus, Giovanni Davogustto, Katherine C. Anderson, M. Benjamin Shoemaker, et al.

    BACKGROUND: Brugada syndrome is an inheritable arrhythmia condition that is associated with rare, loss-of-function variants in SCN5A . Interpreting the pathogenicity of SCN5A missense variants is challenging, and ≈79% of SCN5A missense variants in ClinVar are currently classified as variants of uncertain significance. Automated patch clamp technology enables high-throughput functional studies of ion channel variants and can provide evidence for variant reclassification. METHODS: An in vitro SCN5A –Brugada syndrome automated patch clamp assay was independently performed at Vanderbilt University Medical Center and Victor Chang Cardiac Research Institute. The assay was calibrated according to ClinGen Sequence Variant Interpretation recommendations using high-confidence variant controls (n=49). Normal and abnormal ranges of function were established based on the distribution of benign variant assay results. Odds of pathogenicity values were derived from the experimental results according to ClinGen Sequence Variant Interpretation recommendations. The calibrated assay was then used to study SCN5A variants of uncertain significance observed in 4 families with Brugada syndrome and other arrhythmia phenotypes associated with SCN5A loss-of-function. RESULTS: Variant channel parameters generated independently at the 2 research sites showed strong correlations, including peak I Na density ( R 2 =0.86). The assay accurately distinguished benign controls (24/25 concordant variants) from pathogenic controls (23/24 concordant variants). Odds of pathogenicity values were 0.042 for normal function and 24.0 for abnormal function, corresponding to strong evidence for both American College of Medical Genetics and Genomics/Association for Molecular Pathology benign and pathogenic functional criteria (BS3 and PS3, respectively). Application of the assay to 4 clinical SCN5A variants of uncertain significance revealed loss-of-function for 3/4 variants, enabling reclassification to likely pathogenic. CONCLUSIONS: This validated high-throughput assay provides clinical-grade functional evidence to aid the classification of current and future SCN5A –Brugada syndrome variants of uncertain significance.


  • Open Access

    EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN ALONE ON CORONARY ARTERY LESION REDUCTION IN KAWASAKI DISEASE

    by Ho-Chang Kuo, Ming-Chih Lin, Chung-Chih Kao, Ken-Pen Weng, Yun Ding, Chih-Jung Chen, Sheng-Ling Jan, Kuang-Jen Chien, Chun-Hsiang Ko, Chien-Yu Lin, et al.

    Background Though Aspirin and intravenous immunoglobulin (IVIG) remain the standard treatments for Kawasaki Disease (KD) to minimize coronary artery damage, the duration and dosage of aspirin are inconsistent across hospitals. However, the lack of multi-center randomized trials prevents definitive answers to the impact of high-dose aspirin. Methods This clinical trial was structured as a prospective, evaluator-blinded, multi-center randomized controlled trial with two parallel arms, aiming to assess the effectiveness of IVIG as a standalone primary therapy of KD in comparison to the combination of IVIG with high-dose aspirin therapy. KD patients were enrolled between September, 2016 and August, 2019. A final cohort of 134 patients were randomly assigned to the standard and test groups with 69 and 65 patients, respectively. The Standard group received IVIG (2 g/kg) along with aspirin (80-100 mg/kg/day) until fever subsided for 48 hours. The test group received IVIG (2 g/kg) alone. Following the initial treatment, both groups received a daily aspirin dose (3-5 mg/kg) for six weeks. The primary outcome measure was the occurrence of coronary artery lesions (CAL) at the 6-8 weeks mark. The secondary outcome is IVIG resistance. Results The overall rate of CAL in test group decreased from 10.8% at diagnosis to 1.5% and 3.1% at 6 weeks and 6 months, respectively. The CAL rate of standard group declined from 13.0% to 2.9% and 1.4%, with no statistically significant difference (P>0.1) in the frequency of CAL between the two groups. Furthermore, no statistically significant differences were found for treatment (P>0.1) and prevention (P>0.1) effect between the two groups. Conclusions This marks the first prospective multi-center randomized controlled trial comparing the standard treatment of KD using IVIG plus high-dose aspirin against IVIG alone. Our analysis indicates that addition of high-dose aspirin during initial IVIG treatment is neither statistically significant nor clinically meaningful for CAL reduction. Registration URL: http://www.clinicaltrials.gov; identifier: NCT02951234 What is New? This study represents the first multi-center randomized controlled trial investigating the efficacy of high-dose aspirin or intravenous immunoglobulin (IVIG) during the acute stage of KD. This study assessed the impact of discontinuing high-dose aspirin (80–100 mg/kg/day) on the occurrence of CAL during the acute phase treatment of Kawasaki Disease. No significant differences were observed between high-dose aspirin plus IVIG treatment and IVIG alone treatment in terms of the frequency of abnormal coronary artery abnormalities. Additionally, our analysis revealed no statistically significant differences in either the treatment effect (the number of cases successfully treated) or prevention effect (the prevention of new cases) between these two treatments. What Are the Clinical Implications? Comparison analysis indicated the non-inferiority between two groups with or without high-dose aspirin. Administering the standard 2 g/kg/day IVIG without high-dose aspirin (80–100 mg/kg/day) during the acute phase therapy for KD does not increase the risk of coronary artery lesions, which are a primary cause of morbidity and mortality in KD patients. Addition of high-dose aspirin during initial IVIG treatment is not statistically significant or clinically meaningful.


  • Open Access

    Computational modelling of cardiac resynchronization therapy in congenital heart disease: fantasy or the future?

    by Henry Chubb, Matteo Salvador, Alison L Marsden

    This editorial refers to ‘How to assess and treat right ventricular electromechanical dyssynchrony in post-repair tetralogy of Fallot: insights from imaging, invasive studies and computational modelling’, by M. Ložek et al., https://doi.org/10.1093/europace/euae024.